News

By mixing and matching diffractive and refractive IOLs, patients can achieve much better all round visual results.

Bevacizumab: less effective against larger lesions; New supranational European society; Happy 50th birthday SOE; Blue-blocking IOLs damage health; 3-D test identifies early stage glaucoma; A new way of tackling ROP; Femtosecond not always appropriate; High pulse pressure linked to OAG; Stem cell project to cure AMD underway; OCT increasingly popular for anti-VEGF monitoring; Glaucoma nano-treatment on the horizon; Lucky for some: the 13th LCA gene; Community optometrists able to diagnose glaucoma accurately; Coffee may prevent blepharospasm

Ninety percent achieved the efficacy endpoint, and, furthermore, over two-thirds of patients improved by at least three lines and one-quarter improved by at least five lines in distance vision

Editorial advisory board

Call for papers

The practice of treating angle closure glaucoma (ACG) varies widely across the United Kingdom, according to a poster presented at the 8th congress of the European Glaucoma Society (EGS), held June 1–6 in Berlin.

Current screening and referral methods are thought to be inadequate. But what needs to be done to improve the situation?

Involving the general ophthalmologist in follow-up monitoring is recommended, whilst patient self-monitoring is essential in the long-term.

During the course of therapy, when should fluorescein angiography be performed? Also consider whether the general ophthalmologist could provide some much needed assistance.

Is it necessary to administer intravitreal injections in an operating theatre? Find out how to optimize patient flow during the treatment process.

Is a formal examination necessary following the administration of an intravitreal injection?

A good team structure involving bredth of technical staff is important to ensure smooth patient flow during the initial diagnosis procedure.

Healthcare authorities must be updated on AMD and the importance of new therapies. A system also needs to be implemented which advises on responsibility for payment.

According to some experts, the team approach is preferable to the production-line approach when organizing a clinic that administers intravitreal anti-VEGF therapy.

Sirion Therapeutics has initiated two new Phase III clinical studies for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).

The British intraocular lens (IOL) manufacturer, Rayner Intraocular Lenses, has received pre-market approval (PMA) for its C-flex lens from the FDA making it the first non-US IOL to receive FDA approval in twenty years.

Significantly more glaucoma patients, who are treated surgically rather than medically, will experience reversal of cupping.

Ellex Medical Lasers has received FDA 510(k) approval to market the Ellex 30XL laser slit lamp.

Novagali Pharma's Investigational New Drug Application (IND) to conduct a pivotal Phase III clinical trial of its dry eye candidate, Nova22007, has been granted by the FDA.

A study, which was halted before the completion of enrolment, failed to demonstrate any difference in the visual outcomes or safety concerns in patients with neovascularization secondary to age-related macular degeneration (AMD) who were treated with photodynamic therapy (PDT) in combination with either intravitreal injections of Macugen (pegaptanib sodium) or triamcinolone

QLT has announced that the Committee for Medicinal Products for Human Use (CHMP) will recommend to the European Commission that the occult indication for Visudyne be removed from the product's European label.

ISTA Pharmaceuticals has withdrawn its marketing authorization application for Vitragen.

Optical Coherence Tomography (OCT) provides a convenient and quick method of assessing the configuration of the anterior chamber.

A Swedish initiative for screening the vision of six-years olds has found that those with a visual acuity (VA) of 0.65 rarely have defects that require treatment, making the current criterion of 0.8 too demanding on the available resources.

Medennium has obtained CE mark clearance to market its photochromic intraocular lens (IOL), Aurium in Europe, making it the first lens of its kind to be introduced to the cataract lens market.

M&S Technologies has released a new software for its Smart System 2020 and PC-Plus visual acuity, contrast sensitivity and video media systems.

The US FDA has approved wavefront-guided and mixed astigmatism indications for WaveLight's Allegretto Wave Eye-Q system.

Glaucoma medication compliance and effectiveness of drug administration correlates with age and severity of disease.

Neurotech Pharmaceuticals has begun enrolment for two Phase II/III clinical trials of NT-501; it's lead Encapsulated Cell Technology (ECT) product for the treatment for retinitis pigmentosa (RP).

Alimera Sciences has announced that enrolment for its Phase III global clinical trial, FAME (Fluocinolone Acetonide in Diabetic Macular Edema), has exceeded 50%.